REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

13/02/2023 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230213:nRSM7335Pa&default-theme=true

RNS Number : 7335P  AstraZeneca PLC  13 February 2023

13 February 2023 14:00 GMT

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announced that on 9 February 2023 certain awards
of the Company's ordinary shares of $0.25 each (Ordinary Shares) and the
Company's American Depositary Shares (ADSs) vested to Dr Aradhana Sarin,
Executive Director and Chief Financial Officer. Each ADS represents one half
of an Ordinary Share.

 

Following the reinvestment of dividends and the withholding to satisfy certain
tax obligations arising on vesting, Dr Sarin acquired the ADSs and Ordinary
Shares as detailed in the table below.

 

 PDMR            ADSs acquired under the Alexion equity awards  Ordinary Shares acquired under restricted share award
 Aradhana Sarin  29,362                                         7,514

 

Further details on the awards is also set out below.

 

Alexion equity awards

In accordance with the Agreement and Plan of Merger between the Company and
Alexion Pharmaceuticals, Inc. (Alexion), Dr Sarin's in-flight share awards
granted by Alexion were converted to awards over AstraZeneca ADSs under the
AstraZeneca Global Restricted Stock Plan at the time of closing of the Alexion
acquisition. The awards that vested on 9 February 2023 replaced in-flight
Alexion awards originally granted to Dr Sarin between February 2020 and
February 2021 under the Alexion 2017 Incentive Plan.

 

Restricted share award

Dr Sarin's previous employment contract with Alexion included an entitlement
to cash severance arrangements, which would have been triggered at the date of
closing of the acquisition of Alexion. To compensate Dr Sarin for the
forfeiture of these contractual entitlements an award of £2,015,540 was made
in August 2021, 50% in cash and 50% in restricted shares. The restricted
shares vested and were released to Dr Sarin on 9 February 2023, 18 months
after her appointment.

 

For tax purposes, the fair market value of an ADS at vest of the awards was
US$64.36, being the closing price on the last trading day preceding the
vesting. The fair market value of an Ordinary Share at vest was 10,572 pence,
being the closing price on the last trading day preceding the vesting.

 

Further details are set out in the attached notification, made in accordance
with the requirements of the EU Market Abuse Regulation (as it forms part of
UK law pursuant to the European Union (Withdrawal) Act 2018.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Aradhana Sarin

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification/Amendment                               Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4i   Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  AstraZeneca PLC American Depositary Shares

      Identification code

                                                                   CUSIP: 046353108

 b)   Nature of the transaction                                    Acquisition of AstraZeneca PLC American Depository Shares pursuant to a

                                                            vesting under the Global Restricted Stock Plan

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   0    29,362
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      9 February 2023

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

9 February 2023

f)

 

Place of the transaction

 

Outside a trading venue

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Aradhana Sarin

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification/Amendment                               Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4i   Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of US$0.25 each in AstraZeneca PLC

      Identification code

                                                                   GB0009895292

 b)   Nature of the transaction                                    Acquisition of AstraZeneca PLC Ordinary Shares pursuant to a vesting of a

                                                            Restricted Share Award

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   0    7,514
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      9 February 2023

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

9 February 2023

f)

 

Place of the transaction

 

Outside a trading venue

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUOVRRONUUAAR